FAQ on Clene's Participation in the Emerging Growth Conference

What is Clene Inc. presenting at the Emerging Growth Conference?

Clene Inc. will present a corporate update on its clinical-stage biopharmaceutical developments, focusing on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS and MS.

When is the Emerging Growth Conference taking place?

The Emerging Growth Conference is scheduled for July 18, 2024, with Clene’s presentation starting at 4:45 p.m. EDT.

How can I view Clene’s presentation at the conference?

A webcast of the presentation will be available on Clene’s website, and you can also view it via the link provided: https://ibn.fm/A52lW.

What is CNM-Au8 and what does it target?

CNM-Au8 is an investigational, first-in-class therapy by Clene that improves the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway, while reducing oxidative stress.

Where is Clene Inc. based?

Clene Inc. is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.

Who can attend the Emerging Growth Conference?

The conference is designed for public companies to present to the investment community, including individual and institutional investors, advisors, and analysts.

What are the main neurodegenerative diseases Clene is targeting?

Clene is focusing on treating amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS) through its research and development efforts.

Where can I find more information about Clene Inc.?

For more information about Clene Inc., please visit their official website at www.Clene.com.

What is the significance of Clene’s participation in the Emerging Growth Conference?

Clene’s participation highlights its commitment to advancing treatments for neurodegenerative diseases and provides an opportunity to communicate its progress and innovations to a wide audience of investors and analysts.